Skip to content
Study details
Enrolling now

Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

Virginia Commonwealth University
NCT IDNCT06981195ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 4.2 years

Ages

18+

Locations

1 site in VA

About this study

This trial is testing a treatment called lemborexant for insomnia in people with opioid use disorder. The goal is to see how this medication affects sleep, mood, and behavior. Researchers will compare lemborexant to a placebo (sugar pill) over 8 weeks to measure improvements on these factors.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Lemborexant 10 MG
  • 2.Take Placebo
PhasePhase 2
DrugLemborexant 10 MG
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

lemborexant

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Negative Emotionality: General Anxiety Disorder (GAD-7), Negative Emotionality: Patient Health Questionnaire (PHQ-9)

Body systems

Psychiatry / Mental Health